U.S. Political Developments, Risk Sentiment Survey Results

See how biopharma leaders view the latest policy changes.

Biotech is reeling, fearful and furious about the fallout of tariffs, FDA and NIH policies, says BioCentury’s Risk Sentiment survey

The first half of 2025 may go down as the time when the golden era of biotech gave way to its darkest days in decades. There have been rough periods before, but this one compounds a market collapse with a hollowing out of FDA, the devaluing of scientific research, and the potential decline of U.S. preeminence in biomedical science. That is the inescapable takeaway from a survey of 328 biopharma stakeholders conducted April 10-14.

Want a deeper dive into the data and insights?

Download the Full Survey Results

Thank you to everyone who participated in BioCentury’s survey on recent U.S. political developments and their impact on the biopharma sector.

BioCentury values your privacy. All responses were confidential and are presented in aggregate only.

Subscribers, click here to access BioCentury's risk sentiment survey analysis.

Not a subscriber yet?

Not to worry, we are opening access to survey results. Simply complete the form below to access.